Fingerprint
Dive into the research topics of 'Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically